Back to Newsroom
Back to Newsroom

CLASS ACTION UPDATE for AI, LCID and ABBV: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders

Monday, 11 April 2022 03:45 PM

Levi & Korsinsky, LLP

Topic:
Lawsuits

NEW YORK, NY / ACCESSWIRE / April 11, 2022 / Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the court. Further details about the cases can be found at the links provided. There is no cost or obligation to you.

AI Shareholders Click Here: https://www.zlk.com/pslra-1/c3-ai-inc-loss-submission-form?prid=25822&wire=1
LCID Shareholders Click Here: https://www.zlk.com/pslra-1/lucid-group-inc-loss-submission-form?prid=25822&wire=1
ABBV Shareholders Click Here: https://www.zlk.com/pslra-1/abbvie-inc-loss-submission-form?prid=25822&wire=1

* ADDITIONAL INFORMATION BELOW *

Levi & Korsinsky, LLP, Monday, April 11, 2022, Press release picture

C3.ai, Inc. (NYSE:AI)

This lawsuit is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired: (a) C3.ai Class A common stock pursuant and/or traceable to the documents issued in connection with the Company's initial public offering conducted on or about December 9, 2020; and/or (b) C3.ai securities between December 9, 2020 and February 15, 2022, both dates inclusive.
Lead Plaintiff Deadline : May 3, 2022
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/c3-ai-inc-loss-submission-form?prid=25822&wire=1

According to the filed complaint, (i) C3.ai's partnership with Baker Hughes was deteriorating; (ii) C3.ai was employing a flawed accounting methodology to conceal the deterioration of its Baker Hughes partnership; (iii) C3.ai faced challenges in product adoption and significant salesforce turnover; (iv) the Company overstated, inter alia, the extent of its investment in technology, description of its customers, its total addressable market, the pace of its market growth, and the scale of alliances with its major business partners; and (v) as a result, the Company's public statements were materially false and misleading at all relevant times.

Lucid Group, Inc. (NASDAQ:LCID)

This lawsuit is on behalf of a class of all persons and entities who purchased or otherwise acquired Lucid common stock between November 15, 2021, and February 28, 2022, inclusive.
Lead Plaintiff Deadline: May 31, 2022
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/lucid-group-inc-loss-submission-form?prid=25822&wire=1

The filed complaint alleges that defendants made materially false and/or misleading statements and failed to disclose material adverse facts about Lucid's business and operations. Specifically, the Company overstated its production capabilities while concealing that "extraordinary supply chain and logistics challenges" were hampering Lucid's operations. As a result of the defendants' wrongful acts and omissions, and the significant decline in the market value of Lucid's common stock, Lucid investors have suffered significant damages.

AbbVie Inc. (NYSE:ABBV)

ABBV Lawsuit on behalf of: investors who purchased April 30, 2021 - August 31, 2021
Lead Plaintiff Deadline: June 6, 2022
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/abbvie-inc-loss-submission-form?prid=25822&wire=1

According to the filed complaint, during the class period, AbbVie Inc. made materially false and/or misleading statements and/or failed to disclose that: (1) safety concerns about Pfizer Inc.'s drug Xeljanz extended to Abbvie's drug Rinvoq and to other Janus kinase enzyme inhibitor drugs; (2) as a result, it was likely that the U.S. Food and Drug Administration would require additional safety warnings for Rinvoq and would delay the approval of additional treatment indications for Rinvoq; and (3) therefore, defendants' statements about the Company's business, operations, and prospects lacked a reasonable basis.

You have until the lead plaintiff deadlines to request that the court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

Levi & Korsinsky is a nationally recognized firm with offices in New York, California, Connecticut, and Washington D.C. The firm's attorneys have extensive expertise and experience representing investors in securities litigation and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Eduard Korsinsky, Esq.
55 Broadway, 10th Floor
New York, NY 10006
[email protected]
Tel: (212) 363-7500
Fax: (212) 363-7171
www.zlk.com

SOURCE:Levi & Korsinsky, LLP

Topic:
Lawsuits
Back to newsroom
Back to Newsroom

Contact Us Today


If you have questions or want to learn more about our products, our team’s here to help!

Share by: